首页> 外文会议>IEEE International Conference on Bioinformatics and Biomedicine >Exploring potential therapeutic agents of Duhuo-Jisheng-Tang for rheumatoid arthritis
【24h】

Exploring potential therapeutic agents of Duhuo-Jisheng-Tang for rheumatoid arthritis

机译:探索度活吉生汤治疗类风湿关节炎的潜在治疗剂

获取原文

摘要

Duhuo-Jisheng-Tang is a Chinese herbal formula designed to treat rheumatoid arthritis (RA) with syndrome dual deficiency of liver and kidney. Although its therapeutic clinical effect is widely accepted over one thousand years, its therapeutic agents are still obscure. In this study, we explored the potential therapeutic agents of Duhuo-Jisheng-Tang for RA by integrating leading knowledge databases of different biomedical domains. The molecule mechanism includes compositional herbal medicine, chemical compound, target protein, RA OMIM genes, FDA approved RA drug targets, and pathways. As a result, Duhuo-Jisheng-Tang's 11 target proteins can be found in RA's OMIM genes (e.g., UGT1, UGT1A9, GNT1, and JAK3) and FDA approved RA drug targets (e.g., CMKBR2/5, CCR2/5, APRF, and STAT1/3). What's more, these 11 genes/proteins are mainly enriched in pathways of disease, immune system, signal transduction, and metabolism. It demonstrates that Duhuo-Jisheng-Tang may regulate a wide range of different systems associated with RA which might indicate that Chinese herbal formula's therapeutic effects are demonstrated through system-level regulation rather than targeting disease specified genes/proteins.
机译:独活吉生汤是一种中草药配方,用于治疗具有肝肾双重缺乏症的类风湿性关节炎(RA)。尽管其治疗临床效果在一千多年以来被广泛接受,但其治疗剂仍不清楚。在这项研究中,我们通过整合不同生物医学领域的领先知识数据库,探索了Duhuo-Jisheng-Tang对RA的潜在治疗剂。分子机制包括草药成分,化合物,靶蛋白,RA OMIM基因,FDA批准的RA药物靶标和途径。结果,可以在RA的OMIM基因(例如UGT1,UGT1A9,GNT1和JAK3)和FDA批准的RA药物靶标(例如CMKBR2 / 5,CCR2 / 5,APRF,和STAT1 / 3)。此外,这11种基因/蛋白质主要富含疾病,免疫系统,信号转导和代谢途径。这表明独活吉生汤可能调节与RA相关的各种不同系统,这可能表明中草药配方的治疗作用是通过系统水平的调节而不是针对疾病特定的基因/蛋白质来证明的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号